GlassScriptPhysician profile
Arturo C Taca
NPI 1295846319
$257,798.70
in general payments reported to CMS, 2019-2025
43 companies · $59K in 2025
The $59K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93K · 2020: $30K · 2021: $29K · 2022: $17K · 2023: $20K · 2024: $10K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Travel and Lodging: $8,111 · Food and Beverage: $6,625 · Consulting Fee: $6,460 · Education: $49.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,796.00 |
| Travel and Lodging | $8,111.32 |
| Food and Beverage | $6,625.26 |
| Consulting Fee | $6,460.00 |
| Education | $49.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $186,921.63 | 2019-2025 | Vivitrol, Vivitrol, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51,153.55 | 2021-2025 | Caplyta |
| Mdd US Operations, LLC | $10,433.91 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,183.20 | 2021-2024 | Rejoyn |
| Sunovion Pharmaceuticals INC. | $1,398.56 | 2019-2022 | |
| Abbvie INC. | $723.63 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $712.56 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $589.09 | 2019-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $579.36 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $442.93 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $327.51 | 2025 | Cobenfy |
| Neuronetics, INC. | $299.48 | 2019-2021 | |
| Allergan, INC. | $258.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $212.60 | 2019-2025 | Spravato |
| Lundbeck LLC | $185.21 | 2019-2025 | Rexulti |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arturo Taca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.